Other OTC - Delayed Quote USD

BioCorRx Inc. (BICX)

0.7800 +0.0300 (+4.00%)
At close: May 6 at 1:15 PM EDT
Loading Chart for BICX
DELL
  • Previous Close 0.7500
  • Open 0.7800
  • Bid --
  • Ask --
  • Day's Range 0.7800 - 0.8000
  • 52 Week Range 0.6720 - 2.2200
  • Volume 1,551
  • Avg. Volume 1,053
  • Market Cap (intraday) 6.876M
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4500
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

www.biocorrx.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BICX

Performance Overview: BICX

Trailing total returns as of 5/6/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BICX
0.00%
S&P 500
8.61%

1-Year Return

BICX
57.84%
S&P 500
25.25%

3-Year Return

BICX
70.57%
S&P 500
24.31%

5-Year Return

BICX
85.14%
S&P 500
75.88%

Compare To: BICX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BICX

Valuation Measures

Annual
As of 5/7/2024
  • Market Cap

    6.88M

  • Enterprise Value

    8.64M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    73.00

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    96.95

  • Enterprise Value/EBITDA

    -3.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -404.57%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    89.16k

  • Net Income Avi to Common (ttm)

    -3.77M

  • Diluted EPS (ttm)

    -0.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    65.22k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -883.08k

Company Insights: BICX

People Also Watch